Referências Bibliográficas

Reproduzido de:

Atlas de Leishmaniose Tegumentar Americana: Diagnósticos Clínico e Diferencial [Link Livre para o Documento Original]

Série A. Normas e Manuais Técnicos

MINISTÉRIO DA SAÚDE

Secretaria de Vigilância em Saúde

Departamento de Vigilância Epidemiológica

Brasília / DF – 2006

ABELDA, S. M. et al. Adhesion molecules and inflammatory injuries. Faseb J., [S. l.], v. 8, p. 504-512, 1994.

ADAMS, A. R. D. The granulomatous inflammatory response: a review. Amer. Journ. Pathol, [S. l.], v. 84, p. 164-191, 1976.

AKUFFO, H. O.; BRITTON, S. F. F. Contribution of non-leishmania-specific immunity to resistance to leishmania infection in humans. Clin. Exp. Imm., [S. l.], v. 87, p. 58-64, 1992.

ALEXANDER, J.; RUSSEL, D. Parasites antigens, their role in protection, diagnosis and scape in the leishmaniasis. Curr. Top. Microbiol. Immunol., [S. l.], v. 120, p. 43-67, 1985.

______. The interaction of Leishmania species with macrophages. Adv. Parasitol, [S.l.], v. 31, p. 175-254, 1992.

ALEXANDER, J.; VICKERMAN, K. Fusion of host cell secondary lysosomes with the parasitophoros vacuoles of Leishmania mexicana infected macrophages. Journ. Prot., [S. l.], v. 22, p. 502-508, 1984.

ARAGÃO, H. B. Leishmaniose tegumentar e sua transmissão pelos phlebótomos. Mem. Inst. Oswaldo Cruz, [S. l.], v. 20, p. 177-187, 1927.

______. Transmissão da leishmaniose no Brasil pelo Phlebotomus intermedius. Brazil Médico, [S. l.], v. 36, p. 129, 1922.

ARONSON, N. E. et al. Safety and efficacy of intravenous sodium stibogluconate in the treatment of leishmaniasis: recent US military experience. Clin. Infect. Dis., [S.l.], v. 27, p. 1457-1464, 1998.

BARRAL, A. et al. Polar and subpolar diffuse cutaneous leishmaniasis in Brazil: clinical and immunopathologic aspects. Int. J. Dermatol., [S. l.], v. 34, p. 474-479, 1995.

______. Leishmaniasis in Bahia, Brazil: evidence that Leishmania amazonensis produces a wide spectrum of clinical disease. Am. J. Trop. Med. Hyg., [S. l.], v. 44, p.536-546, 1991.

______. Polar and subpolar diffuse cutaneous leishmaniasis in Brazil: clinical and immunopathologic aspects. Int. Journ. Derm., [S. l.], v. 33, p. 474-479, 1995.

BARRAL-NETTO, M. et al. Imunologia da leishmaniose tegumentar. Rev. Soc. Bras. Med. Trop,. [S. l.], v. 19, p. 173-191, 1986.

______. Transforming growth factor beta in leishmanial infection: parasite scape mechanism. Science, [S. l.], v. 257, p. 545-548, 1992.

______. Human cutaneous leishmaniasis: recent advances in physiopathology and treatment. Eur. Journ. Derm., [S. l.], v. 5, p. 104-113, 1995.

BARROS, M. B. et al. Positive Montenegro skin test among patients with sporotrichosis in Rio de Janeiro. Acta Tropica, [S. l.], v. 93, n. 1, p. 41-7, jan. 2005.

BERG, D. J. et al. Interleukin-10 but not interleukin-4 is a natural suppressant of cutaneous inflammatory responses. J. Exp. Med., [S. l.], v. 182, p. 99-108, 1995.

BERTHO, A. L. et al. An experimental model of the production of metastases in murine cutaneous leishmaniasis. J. Parasitol., [S. l.], v. 80, p. 93-99, 1994.

BITTENCOURT, A.; BARRAL-NETTO, M. Leishmaniasis. In: DOEER, W. (Ed.). Tropical pathology. Berlin: Springer-Verlag, 1995. p. 597-651.

BOGDAN, C.; ROLLINGHOFF, M. The immune response to Leishmania: mechanisms of parasite control and evasion. Intern. J. Parasitol., [S. l.], v. 28, p. 121-34, 1998.

BOGDAN, C. et al. Evasion strategies of Leishmania parasites. Parasitol today, [S. l.], v. 14, p. 183-71, 1990.

BOOM, W. et al. Patterns of cytokine secretion in murine leishmaniasis: correlation with disease progression or resolution. Infect. Immun., [S. l.], v. 20, p. 1131-5, 1990.

BOWDRE, J. H. et al. American mucocutaneous leishmaniasis: culture of a Leishmania species from peripheral blood leukocytes. Am. J. Clin. Pathol., [S. l.], v.75, p. 435-438, 1981.

BRYCESON, A. D. M. Diffuse cutaneous leishmaniasis in Ethiopia I: the clinical and histological features of the disease. Trans. R. Soc. Trop. Med. Hyg., [S. l.], v. 63, p. 708-737, 1969.

______. Visceral leishmaniasis unresponsive to antimonial drugs I: clinical and immunological studies. Trans. R. Soc. Trop. Med. Hyg., [S. l.], v. 79, p. 700-704, 1985a.

______. Visceral leishmaniasis unresponsive to antimonial drugs II: response to high dosage sodium stibogluconate or prolonged treatment with pentamidine. Trans. R. Soc. Trop. Med. Hyg., [S. l.], v. 79, p. 705-714, 1985b.

______. Pathogeneses of diffuse cutaneous leishmaniasis. IV. Trans. Roy. Soc. Trop. Med. Hyg., [S. l.], v. 64, p. 387-393, 1970c.

CÁCERES-DITTMAR, G. et al. Determination of the cytokine profile in American cutaneous leishmaniasis using the polymerase chain reaction. Clin. Exp. Immunol., [S. l.], v. 91, p. 500-505, 1993.

CARINI, A.; PARANHOS, U. Identification de “l’ulcera de Bauru” avec le Bouton d’Orient. Bulletin de la Societé de Pathologie Exotique, [S. l.], v. 2, p. 255-257, 1909.

CARVALHO, E. et al. Imunidade e infecção. Medicina, Ribeirão Preto, v. 28, p. 253-83, 1995.

CARVALHO, E. M. et al. Cell mediated immunity in American cutaneous and mucosal leishmaniasis. Journ. Imm., [S. l.], v. 135, p. 4144 - 4148, 1985.

CASTES, M. et al. Characterization of the cellular immune response in American cutaneous leishmaniasis. Clin. Immunol. Immunopathol, [S. l.], v. 27, p. 176-186, 1983.

CASTES, M. et al. T-cell subpopulations, expression of interleukin-2 receptor, and production of interleukin-2 and gamma interferon in human American cutaneous leishmaniasis. Journal of Clinical Microbiology, [S. l.], v. 26, p. 1207-1213, 1988.

______. T-cells subpopulations, expression of interleukin-2 receptor and production of interleukin-2 and gamma interferon in human American cutaneous leishmaniasis. Journ. Clin. Microb., [S. l.], v. 26, p. 1207-1213, 1988.

CHAN, J. et al. Microbial glucolipids: possible virulence factors that scavenge oxygen radicals. Proc. Natl. Acad. Sci. USA., [S. l.], v. 86, p. 2453-7, 1989.

CHAN, M. M. Y. T-cell response in murine Leishmania mexicana amazonensis infection: production of interferon gamma by CD8 cells. Eur. Journ. Imm., [S. l.], v.23, p. 1181-1184, 1993.

CHANG, K. Leishmanicidal mechanisms of human polymorphonuclear phagocytes. Am. J. Trop. Med. Hyg., [S. l.], v. 30, p. 322-333, 1981.

CONVIT, J. et al. Diffuse cutaneous leishmaniasis: a disease due to an immunological defect of the host. Trans. R. Soc. Trop. Med. Hyg., [S. l.], v. 66, p. 603-610, 1972.

______. The clinical and immunological spectrum of American cutaneuos leishmaniasis. Trans. Roy. Soc. Trop. Med. Hyg., [S. l.], v. 87, p. 444 - 448, 1993.

CORRADIN, S. B.; MAUEL, J. Phagocytosis of Leishmania enhances macrophage activation by IFN gamma and lypopolysaccharide. Journ. Imm., [S. l.], v. 146, p. 279-285, 1991.

COSTA, J. M. Nipple involvement in diffuse cutaneous leishmaniasis (DCL) produced by Leishmania (L) amazonensis. Rev. Soc. Bras. Med. Trop., [S. l.], v. 28, p. 139, 1995.

______. Estudo da leishmaniose cutânea difusa (LCD) no estado do Maranhão - Brasil: avaliação terapêutica e correlação do perfil imunológico entre pacientes e seus familiares. 1998. Tese (Doutorado em Doenças Infecciosas e Parasitárias)–Escola Paulista de Medicina, São Paulo, 1998.

______. Leishmaniose cutânea difusa: revisão. Anais Brasileiros de Dermatologia, v.73, p. 565-576, 1998.

______. Disseminated cutaneous leishmaniasis in a field clinic in Bahia, Brazil: a report of eight cases. Journ. Trop. Med. Hyg., [S. l.], v. 89, p. 319-321, 1986.

______. Estado atual da leishmaniose cutânea difusa no estado do Maranhão: aspectos epidemiológicos, clínico-evolutivos. Rev. Soc. Bras. Med. Trop., [S. l.], v. 25, p. 115-123,1992.

______. Spontaneous regional healing of extensive skin lesions in diffuse cutaneous leishmaniasis (DCL). Rev. Soc. Bras. Med. Trop., [S. l.], v. 28, p. 45-47, 1995.

______. Spontaneous healing of leishmaniasis caused by Leishmania Viannia braziliensis in cutaneous lesions. Rev. Soc. Bras. Med. Trop., [S. l.], v. 23, p. 205-208, 1990.

COURA, J. R. Disseminated American cutaneous leishmaniasis in a patient with aids. Mem. Inst. Oswaldo Cruz, [S. l.]. v. 82, p. 581-582, 1987.

COUTINHO, S. G. et al. Pathogenesis and immunopathology of leishmaniasis. Mem. Inst. Oswaldo Cruz, [S. l.], v. 82, p. 214-228, 1987.

DA-CRUZ, A. M. et al. Leishmania-reactive CD4+ and CD8+ cells associated with cure of human cutaneous leishmaniasis. Inf. Imm., [S. l.], v. 62, p. 2614-2618, 1994.

______. Cellular and humoral immune responses of a patient with American cutaneous leishmaniasis and Aids. Trans. R. Soc. Trop. Med. Hyg., [S. l.], v. 86, p. 511-512, 1992.

DEDET, J. P. et al. Uptake and killing of Leishmania mexicana amazonensis amastigotes by human skin fibroblasts. Ann. Trop. Med. Par., [S. l.], v. 77, p. 35-44, 1983.

DEPS, P. D. et al. Comparative assessment of the efficacy and toxicity of N-methylglucamine and BP88 sodium stibogluconate in the treatment of localized cutaneous leishmaniasis. Rev. Soc. Bras. Med. Trop., [S. l.], v. 33, p. 535-543, 2000.

DEY, P. et al. Fine-needle aspiration cytology of Leishmania lymphadenitis. Diagn. Cytopathol, [S. l.], v. 8, p. 551-552, 1992.

EHLERS, S.; SMITH, K. W. Differentiation of T cell lymphokine gene expression: the in vitro acquisition of T cell memory. J. Exp. Med., [S. l.], v. 173, p. 25-28, 1991.

EL-ON, J. et al. Leishmania donovani: action of excreted factor on hydrolytic enzyme activity of macrophages of mice with genetically different resistance to infection. Exp. Parasitol, [S. l.], v. 49, p. 167-74, 1980.

ESCOBAR, M. A. et al. Concurrent mucosal leishmaniasis and pulmonary tuberculosis. Clin. Infect. Dis., [S. l.], v. 23, p. 836-837, 1996.

FIORENTINO, D. F. et al. Two types of mouse T helper cell IV: Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J. Exp. Med., [S. l.], v. 170, p.2081-95, 1989.

______. Interleukin-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J. Imm., [S. l.], v. 146, p. 3444-3451, 1991.

FRANKE, E. D. et al. Efficacy and toxicity of sodium stibogluconate for mucosal leishmaniasis. Annals of Internal Medicine, [S. l.], v. 113, p. 934-940, 1990.

FURTADO, T; VIEIRA J. B. F. Geografia da leishmaniose tegumentar americana no Brasil. An. Bras. Dermatol, [S. l.], v. 57, p. 135-140, 1982.

GARCIA-GONZALEZ, R. et al. Localized lymphadenitis due to Leishmania. Diagnosis by fine needle aspiration cytology. Postgrad. Med. J., [S. l.], v. 66, p. 326, 1990.

GASSER, R. A. et al.. Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis. Clin. Infect. Dis., [S. l.], v. 18, p. 83-90, 1994.

GLEW, R. et al. Biochemistry of the Leishmania species. Microbiol Rev., [S. l.], v. 52, p. 412-32, 1988.

GOODWIN, L. G. Pentostan (sodium stibogluconate): a 50-year personal reminiscence. Trans. R. Soc. Trop. Med. Hyg., [S. l.], v. 89, p. 339-341, 1995.

GREEN, S. J. et al. Major amastiogotes initiate the L.-arginine-dependent killing mechanism in IFN-? stimulated macrophages by induction of tumor necrosis factor. A. J. Imm., [S. l.], v. 145, p. 4290-4297, 1990.

GREVELINK, S. A.; LERNER, E. A. Leishmaniasis. Am. Acad. Dermatol., [S. l.], v. 34, p. 257-272., 1996.

GRIMALDI, Jr. et al. Review of the geographic distribuition and epidemiology of leishmaniasis in the New World. Am. J. Trop. Med. Hyg., [S. l.], v. 41, p. 687-725, 1989.

GRINSPAN, D. Enfermedades de la boca. Buenos Aires: Editorial Mundi, 1976.

GUERRA, M. et al. Infecção subclínica na leishmaniose tegumentar. An. Bras. Dermatol., [S. l.], v. 60, p. 365-369, 1985.

HALL, L.; TITUS, R. Sand fly vector saliva selectively modulates macrophages functions that inhibit killing of Leishmania major and nitric oxide production. J. Immunol., [S. l.], v. 155, p. 3501-6, 1995.

HARMS, G. et al. Effects of intradermal gamma interferon in cutaneous leishmaniasis. Lancet, [S. l.], v. 92, p. 1287, 1989.

HEINZEL, F. et al. Reciprocal expression of interferon-gamma or interleukin – 4 during resolution or progression of murine leishmaniasis. J. Exp. Med., [S. l.], v. 169, p. 59-72, 1989.

HEPBURN, N. C. et al. Cardiac effects of sodium stibogluconate: myocardial, electrophysiological and biochemical studies. Qjm., [S. l.], v. 87, p. 465-472, 1994a.

______. Hepatotoxicity of sodium stibogluconate therapy for American cutaneous leishmaniasis. Trans. R. Soc. Trop. Med. Hyg., [S. l.], v. 88, p. 453-455, 1994b.

HERMOSO, T. et al. Leishmanial protein kinases phosphorylate components of the complement system. EMBO J., [S. l.], v. 10, p. 4061-7, 1991.

HERWALDT, B. Leishmaniasis. The Lancet, [S. l.], v. 354, p. 1191-9, 1999.

HILL, J. et al. Elimination of CD4 suppressor T cells from susceptible BALB/c mice releases CD8 T lymphocytes to mediate protective immunity against Leishmania. Journ. Exp. Med., [S. l.], v. 169, p. 1819-1827, 1989.

______. Advantages of measuring changes in the number of viable parasites in murine models of experimental cutaneous leishmaniasis. Infect. Immun., [S. l.], v. 39, p. 1087-94, 1983.

HOWARD, J. Host immunity to leishmaniasis. In: CHANG, K.; BRAY, R. (Ed.). Leishmaniasis. Amsterdam: Elsevier, 1981. p. 140-62.

JANEWAY, C.; TRAVERS, P. Imunobiologia: o sistema imunológico na saúde e na doença. Porto Alegre: Artes Médicas, 1997.

JONES, T. C. et al. Epidemiology of American cutaneous leishmaniasis due to Leishmania braziliensis braziliensis. Journal of Infectious Diseases, [S. l.], v. 156, p. 73-83, 1987.

KANJ, L. F.; KIBBI, A. G.; ZAYNOUN, S. Cutaneous leishmaniasis: an unusual case with atypical recurrence. J. Am. Acad. Dermatol., [S. l.], v. 28, p. 495-496, 1993.

KEMENY, D. M. et al. Immune regulation: a new role for the CD8+ T cell. Imm. Today, [S. l.], v. 15, p. 107-110, 1994.

KOS, F. J.; ENGLEMAN, E. G. Immune regulation: a critical link between NK cells and CTLs. Imm. Today, [S. l.], v. 17, p. 175-176, 1996.

KUBBA, R. et al. Dissemination in cutaneous leishmaniasis II: satellite papules and subcutaneous induration. Int. J. Dermatol., [S. l.], v. 27, p. 702-706, 1988.

______. Dissemination in cutaneous leishmaniasis. I: subcutaneous nodules. Int. J. Dermatol., [S. l.], v. 26, p. 300-304, 1987.

LAINSON, R. The American leishmaniases: some observations on their ecology and epidemiology. Trans. R. Soc. Trop. Med. Hyg. [S. l.], v. 77, p. 569-596, 1983.

LAINSON, R.; SHAW, J. J. Epidemiology and ecology of leishmaniasis in Latin-America. Nature, [S. l.], p. 273, p. 595-600, 1978.

______. Evolution, classification and geographical distribution. In: PETERS, W.; KILLICK-KENDRICK, R. (Ed). The leishmaniasis in biology and medicine. London: Academic Press, 1987. v. 1.

______. Leishmaniasis of the New World: taxonomic problems. Br. Med. Bull. [S. l.], v. 28, p. 44-48, 1972.

LAURENTI, M. Aspectos patogênicos da resposta inflamatória aguda induzida experimentalmente em Mesocricetus auratus pela inoculação subcutânea de Leishmania (L) chagasi. (Dissertação de Mestrado)–Faculdade de Medicina Veterinária e Zootecnia, Universidade de São Paulo. São Paulo, 1993

LIEW, F.; O’DONNELL, C. Immunoloy of leishmaniasis. Adv. Parasitol. [S. l.], v. 32, p. 162-222, 1993.

LIEW, F. et al. Macrophage killing of Leishmania parasites in vivo is mediated by nitric oxide from L-arginine. J. Immunol., [S. l.], v. 144, p. 4794-4797, 1990.

LILES, W.; VOORHIS, W. Review nomenclature and biologic significance of cytokines involved in inflammation and the host immune response. J. Infect. Dis. [S. l.], v. 172, p. 1573-1580, 1995.

LINDEMBERG, A. L’ulcère de Bauru ou le bouton d’Orient au Brésil. Bull. Soc. Pathol. Exot. [S. l.], v. 2, p. 252-254, 1909.

LLANOS-CUENTAS, E. A. et al. Leishmaniasis cutanea diseminada asociada a metástasis en mucosas, causada por Leishmania braziliensis braziliensis: fracaso em el hallazgo de parasitos circulantes. Rev. Soc. Bras. Med. Trop. [S. l.], v. 18, p. 271-272, 1985.

LOCKSLEY, R. M.; SCOTT, P. Helper T-cell subsets in mouse leishmaniasis: induction, expansion and effector function. Paras. Today, [S. l.], v. 7, p. 58-61, 1991.

LOUIS, J. A., et al. The in vitro generation and functional analysis of murine T cell populations and clones specific for the protozoan parasite Leishmania tropica. Imm. Rev., [S. l.], v. 61, p. 215-243, 1982.

MANNETTI, R. et al. Natural killer cell stimulatory factor (interleukin - 12) induces T helper type 1 – specific immune responses and inhibits the development of IL-4 producing Th cells. J. Exp. Med., [S. l.], v. 177, p. 1199-1204, 1993.

MARSDEN, P. D. Mucosal leishmaniasis (“espundia” Escomel, 1911). Trans. R. Soc. Trop. Med. Hyg., [S. l.], v. 80, p. 859-876, 1986.

______. The discovery of urea stibamine. Rev. Soc. Bras. Med. Trop., [S. l.], v. 19, p. 115, 1986.

______. Mucosal leishmaniasis (“espundia” Escomel, 1911). Trans. R. Soc. Trop. Med. Hyg., [S. l.], v. 80, 859-876, 1986.

______. Human mucocutaneous leishmaniasis in Três Braços, Bahia – Brazil: an area of Leishmania braziliensis braziliensis transmission. III: mucosal disease presentation and initial evolution. Rev. Soc. Bras. Med. Trop., [S. l.], v.17, p. 179-186, 1984.

______. Spontaneous healing of leishmania braziliensis braziliensis skin ulcers. Trans. R. Soc. Trop. Med. Hyg., [S. l.], v. 78, p. 561-562, 1984.

MARTINEZ, J. E. et al. Haemoculture of leishmania (Viannia) braziliensis from two cases of mucosal leishmaniasis: re-examination of haematogenous dissemination. Trans. R. Soc. Trop. Med. Hyg., [S. l.], v. 86, p. 392-394, 1992.

MARZOCHI, M. C. A. Leishmanioses no Brasil: as leishmanioses tegumentares. Jornal Brasileiro de Medicina, [S. l.], v. 63, p. 82-104, 1992.

MARZOCHI, M. C. A et al. [Indirect immunofluorescence reaction and intradermoreaction for American cutaneous leishmaniasis in residents of the Jacarepagua region (Rio de Janeiro): comparative study of results observed in 1974 and 1978]. Rev. Inst. Med. Trop., São Paulo, v. 22, p. 149-155, 1980.

MARZOCHI, M. C. A.; MARZOCHI, K. B. F. Leishmanioses em áreas urbanas. Rev. Soc. Bras. Med. Trop., [S. l.], v. 30, p. 162-163, 1997.

______. Proposta de uma classificação clínica simplificada para as leishmanioses tegumentares do Novo Mundo. Rev. Soc. Bras. Med. Trop. [S. l.], v. 27, p. 91, 1994.

______. Tegumentary and visceral leishmaniasis in Brazil: emerging anthropozoonosis and possibilities for their control. Cadernos de Saúde Pública, Rio de Janeiro, v. 10, p.359-375, 1994.

______. Proposta de uma classificação clínica simplificada para as leishmanioses tegumentares do Novo Mundo. Rev. Soc. Bras. Med. Trop., [S. l.], v. 1, p. 91, 1994b.

MARZOCHI, M. C. A.; SCHUBACH, A.; MARZOCHI, K. B. F. Leishmaniose tegumentar americana. In: CIMERMAN, B.; CIMERMAN, S. Parasitologia humana e seus fundamentos gerais. São Paulo: Atheneu, 1999.

MATOS, D. S. et al. Differential interferon-gamma production characterizes the cytokine responses to Leishmania and Mycobacterium leprae antigens in concomitant mucocutaneous leishmaniasis and lepromatous leprosy. Clin. Infect., [S.l.], v. 40, n. 2, p. 5-12, jan. 2005.

MATTNER, F.; PADOVA, K.; ALBER, G. Interleukin-12 is indispensable for protective immunity against Leishmania major. Infect. Immun., [S. l.], v. 65, p. 4378-83, 1997.

MATTOS, M. et al. American cutaneous leishmaniasis associated with HIV infection: report of four cases. J. Eur. Acad. Dermatol. Venereol., [S. l.], v. 10, p. 218-225, 1998.

MATTOS, M. S. Clinical, laboratorial and epidemiological aspects of American mucocutaneous leishmaniasis observed in Evandro Chagas Hospital - Fiocruz/RJ from January 1987 to December 1991. Rev. Soc. Bras. Med. Trop., [S. l.], v. 26, p. 261-262, 1993.

MAYRINK, W. et al. Intradermorreação de Montenegro na leishmaniose tegumentar americana após terapêutica antimonial. Rev. Inst. Med. Trop., São Paulo, v. 18, p. 182-185, 1976.

MCMAHON-PRATT, D. et al. Subspecies and species specific antigens of Leishmania mexicana characterized by monoclonal antibodies. Journ. Imm., [S. l.], v. 134, p.1935-1940, 1985.

MELBY, P. C. et al. Increased expression of proinfl ammatory cytokines in chronic lesions of human cutaneous leishmaniasis. Infection and Immunity., [S. l.], v. 62, p.837-842, 1994.

MENDONÇA, M. G. et al. Persistence of Leishmania parasites in scars after clinical cure of American cutaneous leishmaniasis: is there a sterile cure? J. Infect. Dis., [S. l.], v. 189, p. 1018-1023, 2004.

MENDONÇA, S. C., et al. Indirect immunofluorescence test in New World leishmaniasis: serological and clinical relationship. Mem. Inst. Oswaldo Cruz., [S. l.], v. 83, p. 347-355, 1988.

MITCHELL, G. F., HANDMAN, E. Heterologous protection in murine cutaneous leishmaniasis. Emm. Cell. Biol., [S. l.], v. 65, p. 387-392, 1987.

MODABBER, F. Experiences with vaccines against cutaneous leishmaniasis of men and mice. Paras., [S. l.], v. 98, p. 549-560, 1989.

MODLIN, R. L, et al. In situ characterization of the cellular immune response in American cutaneous leishmaniasis. Clin. Exp. Imm., [S. l.], v. 60, p. 241-248,1985.

MOLL, H. Immune responses to parasites: the art of distinguishing the good from the bad. Imm. Today., [S. l.], v. 17, p. 551-552, 1996.

MOLL, H. et al. Langerhans cells transport Leishmania major from infected skin to the draining lymph node presentation to antigen-specific T cells. Eur. J. Immunol., [S. l.], v. 23, p. 1595-601, 1993.

MONTENEGRO, J. A cútis-reação na leishmaniose. Ann. Fac. Med. Univ., São Paulo, v. 1, p. 323:330, 1926.

MORAES, M. A.; CORREIA FILHO, D.; SANTOS, J. B. Lymphadenopathies in American cutaneous leishmaniasis: comments on 2 cases. Rev. Soc. Bras. Med. Trop., [S. l.], v. 26, p. 181-185., 1993

MOREIRA, J. S. Estudo da laringite leishmaniótica. 1994. 118 p. Tese (Mestrado) – Departamento de Cirurgia, Pontifícia Universidade Católica do Rio de Janeiro, Rio

de Janeiro, 1994.

MORRIS, L. et al. Changes in the precursor frequencies of IL-4 and IFN-? secreting CD4+ cells correlate with resolution of lesions in murine cutaneous leishmaniasis. Journ. Imm., [S. l.], v. 149, p. 2715-2721, 1992.

MOSMANN, T.; COFFMAN, R. Two types of mouse helper T-9 cell clone-9 implications for immune regulation. Immunol. Today., [S. l.], v. 8, p. 223-7, 1987.

MOSMANN, T.; CHERWINSKY, H.; BOND, M. Two types of murine helper T cell clone: I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol., [S. l.], v. 136, p. 2348-57, 1986.

MOSMANN, T. R.; COFFMAN, R. L. Heterogenety of cytokine secretion patterns and functions of helper T cells. Adv. Imm., [S. l.], v. 46, p. 111-147, 1989.

NABORS, G. S.; FARRELL, J. P. Depletion of interleukin-4 in BALB/c mice with established Leishmania major infections increases the efficacy of antimony therapy and promotes Th1-like responses. Inf. Imm., [S. l.], v. 62, p. 5498-5504, 1994.

NATHAN, C. F. Identification of interferon-gamma as the lymphokine that activates human macrophages oxidative metabolism and antimicrobial activity. Journ. Exp. Med., [S. l.], v. 158, p. 670-689, 1983.

NETTO, E. M. et al. Recurrence of South American tegumentary leishmaniasis. Lancet, [S. l.], v. 1, p. 501, 1986.

______. Origin of patients with mucosal leishmaniasis in an endemic area of Bahia, Brazil. Rev. Soc. Bras. Med. Trop., [S. l.], v. 19, p. 121-122., 1986.

NEVILLE, B. W. et al. Patologia oral e maxilofacial. Rio de Janeiro: Guanabara Koogan, 1998.

NORTH, R. J. The concept of the activated macrophage. Journ. Imm., [S. l.], v. 121, p. 806 - 816, 1978.

OKELO, G. B.; SANG, D.; BHATT, K. M. The treatment of diffuse cutaneous leishmaniasis: a report of two cases. East. Afr. Med. J., [S. l.], v. 68, p. 67-68, 1991.

OLIVEIRA-NETO, M. P. et al. Active cutaneous leishmaniasis in Brazil, induced by Leishmania donovani chagasi. Mem. Inst. Oswaldo Cruz., [S. l.], v. 81, p. 303-309, 1986.

______. An outbreak of American cutaneous leishmaniasis leishmania braziliensis braziliensis in periurban area of Rio de Janeiro city, Brazil: clinical and epidemiological studies. Mem. Inst. Oswaldo Cruz., [S. l.], v. 83, p. 427-435, 1988.

PAULA, C. D. R. et al. Estudo comparativo de eficácia de isotionato de pentamidina administrada em três doses durante uma semana e de N-metil-glucamina 20mg SbV/kg/dia durante 20 dias para o tratamento da forma cutânea da leishmaniose tegumentar americana. Rev. Soc. Bras. Med. Trop., [S. l.], v. 36, n. 3, p. 365-371, 2003.

PEARSON, R. S.; SOUZA, A. Q. Leishmania species kala-azar, cutaneous and mucocutaneous leishmaniasis. In: MANDEL, G. L.; DOUGLAS, R. G.; BENNET, J. R. Principles and practice of infectious diseases, New York, 1985.

PESSÔA, S. B.; BARRETTO, M. P. Leishmaniose tegumentar americana. Rio de Janeiro: Ministério da Educação e Saúde, 1948. 527 p.

PETERSEN, E. A. et al. Monocyte supression of antigen specific lynphocyte responses in diffuse cutaneous leishmaniasis patient from Dominican Republic. Journ. Imm., [S. l.], v. 132, p. 2603-2606, 1984.

PIRMEZ, C. Immunopathology of American cutaneous leishmaniasis. Mem. Inst. Oswaldo Cruz., [S. l.], v. 87, Suppl. V, p. 105-109, 1992.

POMPEU, M. M. L. Análise imunopatológica do curso da infecção por Leishmania mexicana amazonensis em camundongos BALB/C imunizados. 1998. Dissertação (Mestrado)–Universidade Federal da Bahia, Salvador, 1988.

PUPO, J. A. Estudo clínico de leishmaniose tegumentar americana (Leishmania braziliensis - Vianna 1911). Revista do Hospital das Clínicas, [S. l.], v. 1, p. 113-164, 1946

RABELLO, E. Formes cliniques de la leishmaniose tégumentaire. In: CONGRÈS DES DERMATOLOGISTES ET SYPHILIGRAPHES DE LANGUE FRANÇAISE, 12., 1923, Strasbourg. [Annales...]. Strasbourg: [s.n.], 1923.

______. Les origines de la leishmaniose tégumentaire au Brésil. In: CONGRÈS DES DERMATOLOGISTES ET SYPHILIGRAPHES DE LANGUE FRANÇAISE, 12., 1923, Strasbourg. [Annales...]. Strasbourg: [s.n.], 1923.

RAZIUDDIN, S. Immunoregulatory and proinfl ammatory cytokine production in visceral and cutaneous leishmaniasis. J. Infect. Dis., [S. l.], v. 170, p. 1037-40, 1994.

REGEZI, J. A; SCIUBBA, J. J. Oral pathology: clinical pathologic correlations. 3. ed. Philadelphia: WB Saunders, 1999.

RIBEIRO, A. L. et al. Electrocardiographic changes during low-dose, short-term therapy of cutaneous leishmaniasis with the pentavalent antimonial meglumine. Braz. J. Med. Biol. Res., [S. l.], v. 32, p. 297-301, 1999.

RIDDLEY, D. S. A histological classification of cutaneous leishmaniasis and its geographical expression. Trans. Roy. Soc. Trop. Med. Hyg., [S. l.], v. 74, p. 515 - 521, 1980.

RODA, E. et al. Gamma-interferon production induced by antigens in patients with leprosy and American cutaneous leishmaniasis. Amer. Journ. Trop. Med. Hyg., [S. l.], v. 37, p. 520-524, 1987.

RODRIGUES, M. L. et al. Nephrotoxicity attributed to meglumine antimoniate (Glucantime) in the treatment of generalized cutaneous leishmaniasis. Rev. Inst. Med. Trop., São Paulo, v. 41, p. 33-37, 1999.

ROFFI, I. et al. Detection of circulating antibody in cutaneous leishmaniasis by enzyme-linked immunosorbert assay. Amer. Journ. Trop. Med. Hyg., [S. l.], v. 29, p.183-189, 1980.

ROIG, R. et al. Leishmaniasis in a patient with HIV infection and pulmonary tuberculosis. Is it more than a casual association? Enferm. Infecc. Microbiol. Clin., [S. l.], v. 7, p. 338-339., 1989.

ROMAGNANI, S. Biology of human Th1 and Th2 cells. Journ. Clin. Imm., [S. l.], v. 15, p. 121-129, 1995.

______. Induction of TH1 and TH2 responses: a key role for the “natural” immune response. Imm. Today., [S. l.], v. 13, p. 379-381, 1992.

ROOK, G. Respostas imunes mediadas por células. In: ROITT, I.; BROSTOFF, J.; MALE, D. Imunologia. 2. ed. São Paulo: Manole, 1992. p. 92.

SABROZA, P. C. O domicílio como fator de risco na leishmaniose tegumentar americana: estudo epidemiológico em Jacarepaguá, município do Rio de Janeiro. 1981. Tese (Mestrado)–Escola Nacional de Saúde Pública, Fundação Oswaldo Cruz. Rio de Janeiro, 1981.

SACKS, D.; PERKINS, P. Identification of an infective stage of Leishmania promastigotes. Science, [S. l.], v. 223, p. 1417-9, 1984.

SACKS, D.; BROCLIN, T.; TURCO, S. Developmental modification of the lipophosphoglycan from Leishmania major promastigotes during metacyclogenesis. Mol. Biochem. Parasitol, [S. l.], v. 42, p. 225-34, 1990.

SAENZ, R. E. et al. Efficacy and toxicity of pentostam against Panamanian mucosal leishmaniasis. Am. J. Trop. Med. Hyg., [S. l.], v. 44, p. 394-398, 1991.

SAF’IANOVA, V. M. Classification of the genus Leishmania Viannia Ross: in. the leishmaniasis. Protozoology, v. 1. Leningrado: Academy of Science, 1982.

SALDANHA, A. C. et al. Comparative study between sodium stibogluconate BP 88 and meglumine antimoniate in cutaneous leishmaniasis treatment. II. Biochemical and cardiac toxicity. Rev. Soc. Bras. Med. Trop., [S. l.], v. 33, p. 383-388, 2000.

SAMPAIO, R. N. R. Leishmaniose tegumentar americana no DF. Revista da Sociedade Brasileira de Medicina Tropical, [S. l.], v. 32, n. 5, p. 527-532, 1999.

______. Dificuldades no tratamento da leishmaniose mucosa dificuldades no tratamento da leishmaniose mucosa resistente ao tratamento convencional com antimoniais pentavalentes. Rev. Soc. Bras. Med. Trop. [S. l.], v. 30, p. 143-144, 1997.

SAMPAIO, R. N. R. et al. Estudo comparativo de técnicas de demonstração de amastigotas e isolamento de promastigotas no diagnóstico da leishmaniose tegumentar americana. Anais Brasileiros de Dermatologia, [S. l.], v. 77, n. 5, p. 557-561, 2002.

SAMPAIO, R. N. R.; MARSDEN, P. D. Mucosal leishmaniasis unresponsive to pentavalent antimonial therapy successfuly treated with ambisome. Trans. Roy. Soc. Trop. Med. Hyg., [S. l.], v. 91, p. 77, 1997.

SAMPAIO, R. N. R. et al. Epidemiologia e tratamento da leishmaniose tegumentar americana no Hospital Universitário de Brasília: 406 casos. Rev. Soc. Bras. Med. Trop., [S. l.], p. 03, 2003.

SAMPAIO, R. N. R.; NOGUEIRA, L. S. C. Estudo hospitalar da leishmaniose tegumentar americana (LTA): epidemiologia e tratamento. Anais Brasileiros de Dermatologia, [S. l.], v. 76, n. 1, p. 51-62, 2001.

SAMPAIO, R. N. R. et al. Leishmaniose tegumentar americana associada à aids: relato de quatro casos. Rev. Soc. Bras. Med. Trop., [S. l.], v. 35, n. 6, p. 651-654, 2002.

SAMPAIO, R. N. R. et al. Ineficácia in vivo da terbinafina em leishmaniose cutânea causada por Leishmania (Leishmania) amazonensis em camundongos CTL B57. Rev. Soc. Bras. Med. Trop., [S. l.], v. 36, n. 4, p. 531-533, 2003.

SAMPAIO, R. N. R. et al. The evaluation of the tolerance and nephrotoxicity of pentavalent antimony administered in a dose of 40 mg SbV/kg/day, 12/12 hr, for 30 days in the mucocutaneous form of leishmaniasis. Rev. Soc. Bras.Med. Trop., [S. l.], v. 30, p. 457-463, 1997.

SAMPAIO, R. N. R.; SAMPAIO, J. H.; MARSDEN, P. D. Pentavalent antimonial treatment in mucosal leishmaniasis. Lancet, [S. l.], v. 1, p. 1097, 1985.

SAMPAIO, R. N. R. et al. Leishmaniose tegumentar americana: casuística do Hospital Escola da UnB. Anais Brasileiros de Dermatologia, [S. l.], v. 55, p. 69-76, 1980.

SARAVIA, N. G. et al. Recurrent lesions in human Leishmania braziliensis infection - reactivation or reinfection? Lancet, [S. l.], v. 336, p. 398-402, 1990.

SCHUBACH, A. Avaliação da persistência do parasito na pele de pacientes com leishmaniose tegumentar americana. 1997. 184 p. Tese (Pós-Graduação em Biologia Parasitária)–Instituto Oswaldo Cruz, Rio de Janeiro, 1997.

______. Estudo da evolução da leishmaniose tegumentar americana em pacientes tratados: medicina tropical. 1990. 141 p. Tese. Instituto Oswaldo Cruz, Rio de Janeiro, 1990.

SCHUBACH A. et al. Leishmanial antigens in the diagnosis of active lesions and ancient scars of American tegumentary leishmaniasis patients. Mem. Inst. Oswaldo Cruz, [S. l.], v. 96, p. 987-996, 2001.

SCHUBACH A. et al. Detection of Leishmania DNA by polymerase chain reaction in scars of treated human patients. J. Infect. Dis., [S. l.], v. 178, p. 911-914, 1998.

SCHUBACH, A. et al. Cutaneous scars in American tegumentary leishmaniasis patients: a site of Leishmania (Viannia) braziliensis persistence and viability eleven years after antimonial therapy and clinical cure. Am. J. Trop. Med. Hyg., [S. l.], v. 58, p. 824-827, 1998.

SCOTT, P. Th cell development and regulation in experimental cutaneous leishmaniasis. In: Romagnani, ed. Th1 and Th2 cells in health and disease. Karger, Chem Immunol Basel, [S. l.], v. 63, 1996.

______. IFN-? modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis. J. Immunol., [S. l.], v. 147, p. 3149-55, 1991.

______. Impaired macrophage leishmaniacidal activity at cutaneous temperature. Parasite Immunol., [S. l.], v. 7, p. 277-88, 1985.

SEATON, R. A. et al. Out patient parenteral antimicrobial therapy - a viable option for the management of cutaneous leishmaniasis. Qjm., [S. l.], v. 92, p. 659-667, 1999.

SHAW, J. J.; LAINSON, R. Leishmaniasis in Brazil XI: observations on the morphology of Leishmania of the brazilensis and mexicana complexes. J. Trop. Med. Hyg., [S. l.], v. 79, p. 9-13, 1976.

______. Leishmaniasis in Brazil X: some observations on intradermal reactions to different trypanosomatid antigens of patients suffering from cutaneous and mucocutaneous leishmaniasis. Trans. Roy. Soc. Trop. Med. Hyg., [S. l.], v. 69, p. 323-335, 1975.

SHAW, J. J. Taxonomy of the genus Leishmania: present and future trends and their implications. Mem. Inst. Osw. Cruz, [S. l.], v. 89, p. 471-478, 1994.

SILVA, O. D. Sobre a leishmanose tegumentar e seu tratamento. Mem. Inst. Oswaldo Cruz, [S. l.], v. 7, p. 213-248, 1915.

SILVEIRA, F. T.; LAINSON, R.; CORBETT, C. E. Clinical and immunopathological spectrum of American cutaneous leishmaniasis with special reference to the disease in Amazonian Brazil: a review. Mem. Inst. Oswaldo Cruz, [S. l.], v. 99, p. 239-251, 2004.

SOARES, L. R. B.; BARCINSKI, M. A. Differential production of granulocytemacrophage colony-stimulating factor by macrophages from mice susceptible and resistant to Leishmania mexicana amazonensis. Journ. Leuk. Biol., [S. l.], v. 51, p. 220-224, 1992.

SOUZA, A. Q. et al. Visceral leishmaniasis in Ceará caused by Leishmania braziliensis braziliensis. Mem. Inst. Oswaldo Cruz, [S. l.], v. 84, p. 35, 1989.

SPLENDORE, A. Leishmaniosi con localizzazione nelle cavità mucosa: nuova forma clinica. Bulletin de la Societé de Pathologie Exotique, [S. l.], v. 5, p. 411-438, 1912.

SYPEK, J. P. et al. Resolution of cutaneous leishmaniasis: interleukin-12 initiates a protective T helper type 1 immune response. Journ. Exp. Med., [S. l.], v. 177, p. 1797-1802, 1993.

TALLADA, N. et al. Leishmania lymphadenitis diagnosed by fine-needle aspiration biopsy. Diagn. Cytopathol. [S. l.], v. 9, p. 673-676, 1993.

THAKUR, C. P.; KUMAR, K. Efficacy of prolonged therapy with stibogluconate in post kala-azar dermal leishmaniasis. Indian. J. Med. Res., [S. l.], v. 91, p. 144-148, 1990.

TITUS, R. G.; KELSO, A.; LOUIS, J. Intracellular destruction of Leishmania tropica by macrophages activated with macrophage activating factor/interferon. Clin. Exp. Imm., [S. l.], v. 55, p. 157-165, 1984.

TOMMASI, A. P. Diagnóstico bucal. São Paulo: Medisa S/A, 1977.

TORREALBA, J. et al. Concomitant cutaneous leishmaniasis and leprosy in Venezuela. Trans. R. Soc. Trop. Med. Hyg., [S. l.], v. 89, p. 69, 1995.

VEXENAT, A. C.; SANTANA, J. M.; TEIXEIRA, A. R. L. Cross-rectivity of antibodies in human infections by the kinetoplastid protozoa Trypanosoma cruzi, Leishmania chagasi and Leishmania braziliensis. Rev. Inst. Med. Trop., São Paulo, v. 38, p. 177-185, 1996.

VIANNA, G. Com. à sessão de 24 de abril de 1912 da Sociedade Brasileira de Dermatologia. Bol. Soc. Brasil. Dermat., [S. l.], v. 1, p. 36-38, 1912.

______. Sobre o tratamento da leishmaniose tegumentar. Annaes Paulistas de Medicina e Cirurgia, [S. l.], v. 2, p. 167-169, 1914.

______. Sobre uma nova espécie de Leishmania (Nota preliminar). Brazil Médico, [S.l.], v. 25, p. 411, 1911.

VILLELA, F. Dados estatísticos sobre a leishmaniose das mucosas em Araçatuba, São Paulo. Folha Med. Rio de Janeiro, [S. l.], v. 20, p. 243-244, 1939.

VILLELA, F.; PESTANA, B. R.; PESSÔA, S. B. Presença de Leishmania braziliensis na mucosa nasal sem lesão aparente em casos recentes de leishmaniose cutânea. Hospital, v. 16, [S. l.], p. 953-960, 1939.

WALTON, B. C.; CHINEL, L. V.; EGUIA, O. E. Onset of espundia after many years of occult infection with Leishmania braziliensis. Am. J. Trop. Med. Hyg., [S. l.], v. 22, p.696-698, 1973.

WEIGLE, K. A. et al. Recurrences of tegumentary leishmaniasis. Lancet, [S. l.], v. 2, p.557-558, 1985.

WOOD, N. K.; GOAZ, P. W. Differential diagnosis of oral and maxillofacial lesions. 5.ed. St. Louis: CV. Mosby, 1997.

WRIGHT, S.; SILVERSTEIN, S. Receptors for C3b and C3bi promote phagocytosis but not the release of toxic oxygen from human phagocytes. J. Exp. Med., [S. l.], v.158, p. 2016-23, 1983.

SOBRE OS DIREITOS AUTORAIS DO DOCUMENTO

Consta no documento:

“Todos os direitos reservados. É permitida a reprodução parcial ou total desta obra, desde que citada a fonte e que não seja para venda ou qualquer fim comercial.”

O objetivo do site MedicinaNet e seus editores é divulgar este importante documento. Esta reprodução permanecerá aberta para não assinantes indefinidamente.